Insight · Eye care · ASC payment
The 2027 ASC update is positive. Eye ASC pay still goes down.
CMS finalized a 2.3% ASC update for 2027 on November 4, 2026. Its own impact table shows eye ASC payments down 1% and cataract 66984 down 2%, while musculoskeletal and spine rise 6%. Here is why, which eye codes move, and what changes on drug and device lines.
By ASP-RCM Editorial, Healthcare RCM Practice · Updated
The question for your ASC finance team
If the ASC update is 2.3%, why does your cataract facility fee go down in 2027?
ASC update for 2027
Hospital market basket 3.2% minus 0.9 point productivity, final rule CMS-1850-FC
ASC conversion factor
For ASCs meeting quality reporting. $56.592 for ASCs that fail ASCQR
ASC weight scalar
Down from 0.872 in 2026. It scales the non-device part of every ASC rate
Eye ASC payments, CMS estimate
Eye specialty group, $2,120M in 2026 ASC payments, per RIA Table 113
Why a 2.3% update turns into a cut for eye ASCs
CMS explains the mechanism in the final rule. Specialties built on device-intensive procedures gain. Specialties with few of them, like eye, lose.
OPPS weights rise
The final 340B drug payment policy is offset by a budget-neutral increase in OPPS surgical payment rates.
Device portions go up
ASC device portions of device-intensive procedures use the OPPS conversion factor, so they rise with OPPS.
Scalar drops to 0.814
To keep ASC spending budget neutral, CMS scales down the non-device portions of all other ASC procedures.
Eye codes absorb it
Procedures that are not device-intensive get a small increase or a decrease. CMS shows eye at -1% and 66984 at -2%.
Where eye ASC dollars sit, and the 2027 change
Estimated CY2026 Medicare ASC payments in millions, with CMS's estimated 2027 percent change for each code from RIA Table 114.
Source: CY2027 OPPS/ASC final rule with comment period (CMS-1850-FC), RIA Tables 113 and 114. Aggregate CMS estimates, not code-level rates. Final ASC rates by code are in Addendum AA.
Worked example: one cataract case, both claims
An illustration built only from public CMS figures, not a client result. National, unadjusted Medicare amounts. Your locality and contracts will differ.
| Claim | 2026 | 2027 | Change |
|---|---|---|---|
| Surgeon fee, 66984 (facility), PFS | $462.60 | $442.12 | -$20.48 (-4%) |
| ASC facility, 66984, CMS aggregate estimate | Per $100,000 paid | About $98,000 | -2% |
| ASC facility, 66991, CMS aggregate estimate | Per $100,000 paid | About $109,000 | +9% |
Surgeon fee: CMS CY2027 PFS final rule, Impact on Payment for Selected Procedures. ASC rows apply the RIA Table 114 percentage to a $100,000 base.
Eye drug and device items in the 2027 final rule
These change what an ASC can bill on its own line, or when a product stops being paid separately.
| Item | Code | 2027 status in the final rule |
|---|---|---|
| iDose TR travoprost implant | J7355 with 0660T | Drug pass-through runs through June 30, 2027. CMS kept 0660T at status J1 and will set J7355's status after pass-through ends |
| Aflibercept HD and avacincaptad pegol | J0177, J2782 | Pass-through status ends December 31, 2026 (Table 57) |
| Aflibercept-ayyh biosimilar | Q5147 | Pass-through continues, listed to March 31, 2028 |
| Omidria and Dextenza | J1097, J1096 | On the final list of non-opioid products paid separately in 2027 under section 4135 (Table 96) |
| Dextenza insertion | 68841 | Stays in APC 5503 with no separate payment |
| Trabecular meshwork drainage device, no cataract | 0671T | Device-intensive status continues in the ASC |
| Laser trabeculotomy with OCT guidance | 0730T | Added to ASC lists from April 2026. CMS refused device-intensive status for its patient interface |
Covered procedures list and quality reporting
618 codes added to the ASC list
Most come off the Inpatient Only list. The eye additions are new codes: 0730T laser trabeculotomy and 1084T suprachoroidal scaffold allograft.
ASCQR: no new eye measures
CMS finalized no ASCQR changes beyond removing the colonoscopy follow-up measure. Unplanned Anterior Vitrectomy and Wrong Site stay mandatory.
Cataract visual function stays voluntary
Cataracts: Improvement in Visual Function within 90 Days remains voluntary through the CY2032 payment determination. No penalty for not reporting it.
Miss ASCQR, lose 2 points
An ASC that fails reporting gets a 0.3% update instead of 2.3%, so its conversion factor is $56.592, about 2% lower on every Medicare case.
Dates eye ASCs should load now
- Nov 4, 2026
CY2027 OPPS/ASC final rule (CMS-1850-FC) on display.
- Dec 31, 2026
Pass-through ends for J0177 and J2782 in the facility setting.
- Jan 1, 2027
New ASC rates, conversion factor $57.721, weight scalar 0.814. Same day, the surgeon fee for 66984 drops to $442.12 nationally.
- Jun 30, 2027
Last day of pass-through for iDose TR (J7355).
- Jul 1, 2027
Eight more botulinum toxin codes need prior authorization in hospital outpatient departments. ASCs follow the separate blepharoplasty prior authorization demonstration.
Is your eye ASC ready for January 1?
Tick what is already done.
For eye ASCs, 2027 is a cut hidden inside a positive update. Model cataract revenue on both the surgeon and facility claim, reprice contracts tied to Medicare ASC rates, and fix drug and device lines before January 1.
Questions operators ask next
What is the 2027 ASC conversion factor?
CMS finalized $57.721 for ASCs that meet quality reporting requirements. It is the 2026 factor of $56.322 times the 2.3% update and a wage index budget neutrality factor of 1.0018. ASCs that fail ASCQR get a 0.3% update, a conversion factor of $56.592.
Why do cataract ASC payments go down in 2027?
The ASC weight scalar fell from 0.872 to 0.814. CMS scales only the non-device portions of ASC rates, and device portions rose with the OPPS. Procedures that are not device-intensive absorb the difference. CMS estimates 66984 ASC payments fall 2% and the eye group falls 1%.
Which eye code gains in the 2027 ASC rule?
CMS estimates 66991, cataract surgery with insertion of an intraocular anterior segment drainage device, rises 9% in aggregate ASC payments. Most other high-volume eye codes fall, including 66984 and 66982 at 2%, 66821 at 3%, 65820 at 1% and 15823 at 5%. These are aggregate CMS estimates, so check each code in Addendum AA.
When does iDose TR pass-through end?
The final rule lists pass-through for J7355 through June 30, 2027. After that the drug is no longer paid separately under pass-through. A commenter said its cost exceeds the APC 5492 payment for 0660T. CMS kept 0660T at status J1 and will decide J7355's later status separately.
Want your 2027 eye ASC numbers before January?
Send us 90 days of ASC remits for cataract, MIGS and oculoplastics. A senior ophthalmology billing partner maps the 2027 rate change by code and site, flags drug and device lines that change, in a free 30-minute call with a written gap report after.
Keep reading
Sources
- CMS, CY2027 OPPS and ASC payment system final rule fact sheet, November 4, 2026
- Federal Register public inspection, CMS-1850-FC display copy (RIA Tables 113 and 114, Tables 57, 58, 96)
- CMS, ASC regulations and notices, CMS-1850-FC (Addenda AA and BB)
- CMS, CY2027 PFS final rule CMS-1848-F (Addendum B, Impact on Payment for Selected Procedures)
Checked November 6, 2026. Figures are national Medicare estimates from the CY2027 final rules displayed November 4, 2026, which may be corrected. Code-level ASC rates are in Addendum AA. General information, not legal or reimbursement advice.